3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Phase 2
1
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Breast
1
Conditions
Breast Neoplasms
257
Carcinoma, Non-Small-Cell Lung
213
Ovarian Neoplasms
134
Lung Neoplasms
107
Esophageal Neoplasms
69
Triple Negative Breast Neoplasms
64
Stomach Neoplasms
58
Fallopian Tube Neoplasms
56
Squamous Cell Carcinoma of Head and Neck
52
Neoplasm Metastasis
50
Head and Neck Neoplasms
44
Esophageal Squamous Cell Carcinoma
43
Carcinoma, Ovarian Epithelial
42
Neoplasms
36
Endometrial Neoplasms
34
Uterine Cervical Neoplasms
32
Recurrence
29
Adenocarcinoma Of Esophagus
24
Adenocarcinoma of Lung
22
Urinary Bladder Neoplasms
21
Melanoma
20
Carcinoma, Squamous Cell
19
Carcinoma
18
Small Cell Lung Carcinoma
17
Prostatic Neoplasms
15
Breast Neoplasms, Male
15
Adenocarcinoma, Bronchiolo-Alveolar
13
Peritoneal Neoplasms
12
Inflammatory Breast Neoplasms
12
Testicular Neoplasms
10
Interventions
Gemcitabine
26
Capecitabine
16
Oxaliplatin
14
Fluorouracil
13
Cisplatin
12
Leucovorin
9
pembrolizumab
5
Erlotinib Hydrochloride
5
Bevacizumab
5
durvalumab
4
Trastuzumab
4
Specimen Handling
4
Sorafenib
4
Magnetic Resonance Spectroscopy
4
130-nm albumin-bound paclitaxel
4
trifluridine tipiracil drug combination
3
Lapatinib
3
Irinotecan
3
Carboplatin
3
Biopsy
3
tremelimumab
2
toripalimab
2
regorafenib
2
lenvatinib
2
dehydroftorafur
2
cobimetinib
2
atezolizumab
2
anlotinib
2
Nivolumab
2
N-(3-chloro-4-((3-fluorobenzyl)oxy)phenyl-6-(5-((methylsulfonyl)ethyl)aminomethyl)-2-furyl)-4-quinazolinamine
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Gallbladder Neoplasms
×
Paclitaxel
×
Clear all
NCT05007106
2025-08-14
KEYVIBE-005
Merck Sharp & Dohme LLC
Phase 2
Completed
613 enrolled